Neuphoria Therapeutics (NEUP) Enterprise Value (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Enterprise Value of -$19.4 million for Q1 2026, down 14.06% year-over-year from -$22.6 million in Q1 2025, and up 12.63% quarter-over-quarter from -$22.3 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Enterprise Value (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Enterprise Value for 7 consecutive years, with -$19.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 14.06% year-over-year to -$19.4 million; the TTM figure through Mar 2026 stood at -$19.4 million (down 14.06% YoY), while the FY2025 annual figure was -$14.3 million, down 13.33% from the prior year.
- Enterprise Value advanced to -$19.4 million in Q1 2026 per NEUP's latest filing, from -$22.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$4.3 million in Q4 2024 and bottomed at -$24.0 million in Q2 2022.
- Historically, Enterprise Value has averaged -$13.4 million across 5 years, with a median of -$12.6 million in 2024.
- Annual changes were most pronounced in 2024 — Enterprise Value surged 57.22% — and 2025, when it slumped 412.13%.
- Neuphoria Therapeutics' Enterprise Value stood at -$24.0 million in 2022, then soared by 57.76% to -$10.2 million in 2023, then jumped by 57.22% to -$4.3 million in 2024, then plunged by 412.13% to -$22.3 million in 2025, then gained by 12.63% to -$19.4 million in 2026.
- Business Quant data shows NEUP's Enterprise Value at -$19.4 million in Q1 2026, -$22.3 million in Q4 2025, and -$13.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | -19.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.44 Mn |
| Dec 31, 2025 | -22.25 Mn |
| Sep 30, 2025 | -13.68 Mn |
| Jun 30, 2025 | -14.29 Mn |
| Mar 31, 2025 | -17.04 Mn |
| Dec 31, 2024 | -4.34 Mn |
| Sep 30, 2024 | -8.08 Mn |
| Jun 30, 2024 | -12.61 Mn |
| Mar 31, 2024 | -8.43 Mn |
| Dec 31, 2023 | -10.15 Mn |
| Sep 30, 2023 | -8.14 Mn |
| Jun 30, 2023 | -12.20 Mn |
| Jun 30, 2022 | -24.04 Mn |
| Jun 30, 2021 | -22.28 Mn |
| Jun 30, 2020 | -3.00 Mn |